IM
IMNM.US Immunome Inc
- Market cap
- USD 2.22B
- P/E
- -
- P/B
- 4.88x
- ROE
- -62.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IMNM.US undervalued?
Graham numberThe Graham number of Immunome Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Immunome Inc fundamental analysis
No fundamental analysis for Immunome Inc yet.
Immunome Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Immunome Inc
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase …
Full company profileImmunome Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Immunome Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 6.63M | 14.0M | 9.04M | 6.94M | 0.00 |
| Gross Profit | -521K | -615K | -755K | -755K | -631K | 14.0M | 9.04M | 3.99M | - |
| Operating Income | -7.74M | -10.3M | -12.3M | -25.2M | -36.9M | -110M | -306M | -214M | -304M |
| EBITDA | -7.18M | -9.72M | -11.5M | -23.9M | -36.3M | -28.0M | -151M | -209M | -280M |
| Net Income | -7.85M | -10.6M | -17.1M | -24.7M | -36.9M | -107M | -293M | -212M | -284M |
| EPS | -7.18 | -1.84 | -1.69 | -2.14 | -3.04 | -5.38 | -5.00 | -2.43 | -2.50 |
| Balance Sheet | |||||||||
| Total Assets | 4.45M | 5.06M | 44.5M | 57.9M | 24.0M | 149M | 240M | 683M | 506M |
| Total Liabilities | 29.7M | 40.7M | 3.18M | 9.74M | 7.39M | 28.7M | 59.1M | 48.8M | 51.2M |
| Shareholders' Equity | -25.2M | -35.6M | 41.3M | 48.2M | 16.7M | 120M | 181M | 634M | 454M |
| Cash & Short-term Investments | 1.60M | 2.54M | 39.8M | 49.2M | 20.3M | 138M | 217M | 653M | 462M |
| Total Debt | 1.18M | 564K | 613K | 317K | 291K | 1.65M | 4.83M | 3.86M | 11.4M |
| Cash Flow | |||||||||
| Operating Cash Flow | -7.41M | -9.60M | -12.1M | -18.2M | -28.7M | -7.57M | -111M | -191M | -241M |
| Capital Expenditure | 228K | 233K | 586K | 79.0K | 248K | 831K | 53.5M | 9.69M | 7.56M |
| Free Cash Flow | -7.63M | -9.83M | -12.7M | -18.3M | -28.9M | -8.40M | -164M | -201M | -249M |
| Ratios | |||||||||
| ROE | - | - | -41.4% | -51.3% | -221.6% | -89.1% | -161.7% | -33.5% | -62.4% |
| ROA | -176.4% | -208.5% | -38.5% | -42.7% | -153.4% | -71.9% | -121.9% | -31.1% | -56.1% |
| Net Profit Margin | - | - | - | - | -556.8% | -761.9% | -3,240.4% | -3,060.0% | - |
| Debt to Equity | - | - | 0.01x | 0.01x | 0.02x | 0.01x | 0.03x | 0.01x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Immunome Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 49.0K | 0.00 | - |
| 2019 | USD 4.62M | 0.80 | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Immunome Inc
- Insiders 6.53%
- Institutions 93.47%
- Public & others 0.00%
- Shares outstanding 118M
- Free float 113M
Top funds holding IMNM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock | 7.38M | 6.49% | +0.24% | Sep 2026 |
| Fidelity Growth Company Fund | 4.90M | 4.31% | +0.31% | Aug 2026 |
| T. Rowe Price Instl Small-Cap Stock | 3.97M | 3.49% | -1.12% | Sep 2026 |
| Vanguard Health Care Inv | 3.70M | 3.26% | +29.21% | Sep 2026 |
| PRIMECAP Odyssey Aggressive Growth | 3.69M | 3.25% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.49M | 3.07% | +7.95% | Sep 2026 |
| iShares Russell 2000 ETF | 2.66M | 2.34% | 0.00% | Oct 2026 |
| Fidelity Select Biotechnology | 2.13M | 1.88% | 0.00% | Aug 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.09M | 1.84% | +2.69% | Oct 2026 |
| T. Rowe Price Small-Cap Value | 1.67M | 1.47% | 0.00% | Sep 2026 |
| Fidelity Growth Company K6 | 1.42M | 1.25% | +0.31% | Aug 2026 |
| Fidelity Series Growth Company | 1.25M | 1.10% | +0.32% | Aug 2026 |
| Fidelity Small Cap Index | 1.15M | 1.02% | +0.13% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 989K | 0.87% | -0.38% | Oct 2026 |
| T. Rowe Price Health Sciences | 797K | 0.70% | 0.00% | Sep 2026 |
| Heptagon Driehaus US Micro Cap Eq C$ Acc | 765K | 0.67% | 0.00% | Sep 2026 |
| JPMorgan Small Cap Growth A | 631K | 0.55% | -25.22% | Sep 2026 |
| Vanguard Russell 2000 ETF | 613K | 0.54% | +1.13% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 606K | 0.53% | +0.24% | Oct 2026 |
| BNP Paribas US Small Cap ClassicC | 571K | 0.50% | -0.76% | Sep 2026 |
Top institutions holding IMNM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Investment Management,Inc. | 19.7M | 17.31% | +20.24% | Jun 2026 |
| FMR Inc | 17.0M | 14.95% | +0.10% | Jun 2026 |
| BlackRock Inc | 8.81M | 7.75% | +7.80% | Jun 2026 |
| State Street Corp | 5.49M | 4.83% | +1.75% | Jun 2026 |
| Wellington Management Company LLP | 5.21M | 4.58% | +10.11% | Jun 2026 |
| Redmile Group, LLC | 4.91M | 4.32% | -11.64% | Jun 2026 |
| PRIMECAP Management Company | 4.64M | 4.09% | +1.38% | Sep 2026 |
| Vanguard Capital Management, LLC | 4.55M | 4.00% | +2.74% | Jun 2026 |
| Driehaus Capital Management LLC | 4.35M | 3.82% | +6.01% | Jun 2026 |
| Enavate Sciences GP, LLC | 3.61M | 3.18% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 2.75M | 2.42% | +7.58% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.41M | 2.12% | -15.26% | Jun 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.02M | 1.77% | +9.01% | Jun 2026 |
| JPMorgan Chase & Co | 1.85M | 1.63% | -33.45% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.77M | 1.56% | -37.97% | Jun 2026 |
| Sofinnova Ventures | 1.72M | 1.51% | +1.08% | Jun 2026 |
| Readystate Asset Management LP | 1.61M | 1.41% | +23.35% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.51M | 1.33% | +37.31% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.35M | 1.19% | +33.96% | Jun 2026 |
| BNP Paribas Investment Partners SA | 1.25M | 1.10% | +13.89% | Jun 2026 |
Immunome Inc company profile
- Company name
- Immunome Inc
- Ticker
- IMNM.US
- Exchange
- USA Stocks
- Listed since
- Oct 2, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 267
- Fiscal year end
- December
- Address
- 18702 North Creek Parkway, Bothell, WA, United States, 98011
- Phone
- 425 939 7410
- Website
- immunome.com
About Immunome Inc
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Immunome Inc management
7- Dr. Clay B. Siegall Ph.D.Chairman, President & CEO · born 1961
- Mr. Max RosettChief Financial Officer · born 1990
- Dr. Robert J. Lechleider M.D.Chief Medical Officer · born 1961
- Dr. Philip TsaiChief Technical Officer · born 1968
- Dr. Jack Higgins Ph.D.Chief Scientific Officer · born 1980
- Ms. Sandra G. Stoneman Esq., J.D.Chief Legal Officer, General Counsel & Corporate Secretary · born 1973
- Mr. Roee ShaharExecutive Vice President of Commercial